Evaluation of toxicities for intravesical drugs in phase 1 bladder cancer trials
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34508
Abstract: Improving clinical trial design is important for optimizing approval of safe and effective drugs. Phase 1 clinical trials seek to determine phase 2 doses by investigating predefined dose‐limiting toxicities. Traditional definitions of dose‐limiting toxicity may… read more here.
Keywords: cancer trials; bladder cancer; cancer; drugs phase ... See more keywords
Anti-acne drugs in phase 1 and 2 clinical trials
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2017.1337745
Abstract: ABSTRACT Introduction: Despite the impressive increase of knowledge on acne etiology accumulated during the last 20 years, few efforts have been overtaken to introduce new therapeutic regiments targeting the ideal treatment of acne. The increasing… read more here.
Keywords: acne; acne drugs; clinical trials; anti acne ... See more keywords
Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2018.1533550
Abstract: ABSTRACT Introduction: Psoriasis is a common immune disorder for which there are many FDA-approved therapies. Older oral drugs had limited efficacy and considerable side effects. Biologics have been a major advance but require self-administered injections,… read more here.
Keywords: investigational drugs; oral drugs; clinical trials; psoriasis ... See more keywords
Investigational drugs in phase II clinical trials for acute coronary syndromes
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2020.1708324
Abstract: ABSTRACT Introduction: Despite current guideline-based, secondary prevention strategies in patients with the acute coronary syndrome, the residual ischemic risk is still at an unacceptable rate, and there is a concomitant high bleeding event rate. These… read more here.
Keywords: investigational drugs; acute coronary; phase trials; phase clinical ... See more keywords